BrightSpring Health Services (NASDAQ: BTSG) announced on June 18, 2025, that its specialty pharmacy division Onco360 has been selected as the national pharmacy partner for three newly approved therapies targeting advanced cancers and rare genetic disorders. The partnership positions Onco360 to deliver specialized pharmaceutical services for patients with neurofibromatosis type 1, advanced ovarian cancer, and metastatic lung cancer.
Therapeutic Portfolio Expansion
Onco360 will serve as the national pharmacy partner for three distinct medication therapies addressing different patient populations. GOMEKLI has received approval for treating adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas not amenable to complete resection.
The partnership also includes AVMAPKI FAKZYNJA CO-PACK, approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Additionally, IBTROZI has been approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Comprehensive Patient Support Services
Through this partnership, Onco360 will provide access, education, data management, and expert support for patients diagnosed with these complex conditions. The specialty pharmacy will leverage its established infrastructure to deliver these innovative treatments to patients across all 50 states.
"At Onco360, we continue to partner with innovators and manufacturers to deliver groundbreaking medicines and therapies to patients facing serious, life-threatening conditions, giving them additional hope," said BrightSpring President and CEO Jon Rousseau. "We're proud of the rapid and pioneering work done every day by our specialty teams at Onco360 and CareMed pharmacies to expand care options and treatment alternatives for patients with cancer, rare, and complex disease."
Market Position and Infrastructure
BrightSpring Health Services operates as a comprehensive healthcare platform providing home- and community-based pharmacy and health solutions for complex populations requiring specialized care. The company serves over 400,000 customers, clients, and patients daily across all 50 states through its integrated service lines including pharmacy, home health care, primary care, and rehabilitation and behavioral health services.
Onco360, founded in 2003, operates as a leading independent oncology pharmacy and clinical support services company. The specialty pharmacy maintains a network of URAC- and ACHC-accredited facilities and serves as a flagship brand of PharMerica Corporation. The company was established to integrate stakeholders in the cancer treatment process and address the specialized needs of oncologists, patients, hospitals, cancer centers, manufacturers, health plans, and payers.
